MoonLake Immunotherapeutics (MLTX)’s stock has witnessed a price declined of -1.09% from the previous close with its current price standing at $52.68. Its current price is -14.85% under its 52-week high of $61.87 and 67.66% more than its 52-week low of $31.42.
How does MoonLake Immunotherapeutics (MLTX) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.
MoonLake Immunotherapeutics (MLTX): Earnings History
If we examine MoonLake Immunotherapeutics’s recent earnings history, in the last quarter ended on 6/30/2025, it posted adjusted earnings per share of -$0.87, beating the consensus of -$0.76. In other words, it beat the consensus by -$0.11, resulting in a -14.28% surprise. In the 3 months period before the previous quarter which was closed on 6/30/2025, the stock recorded adjusted earnings per share of -$0.87 in contrast with the Outlook of -$0.76. That was a difference of -$0.11 and a surprise of -14.28%.
MoonLake Immunotherapeutics (NASDAQ: MLTX) Ownership Details
I will give a breakdown of the key shareholders in MoonLake Immunotherapeutics (MLTX). Recent figures show that the company’s insiders hold 15.41% of shares. A total of 194 institutional investors hold shares in the company, making 94.84% of its stock and 112.12% of its float.
Jun 30, 2025, it was reported that the Company’s largest institutional holder is T. Rowe Price Health Sciences Fund, Inc. holding total of 1.1 shares that make 1.73% of the company’s total number of shares and are currently priced at 58.0 million.
The securities firm Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund holds 740.92 shares of MLTX, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 1.17%, and the holding percentage of shares is valued at 39.19 million.
